Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06259526
Other study ID # TSL-CM-JS1-1-01-?
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 26, 2023
Est. completion date April 26, 2025

Study information

Verified date February 2024
Source Tasly Pharmaceutical Group Co., Ltd
Contact Gang Wang, Doctors
Phone 010-58303236
Email adgangwang@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression


Recruitment information / eligibility

Status Recruiting
Enrollment 260
Est. completion date April 26, 2025
Est. primary completion date April 26, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - All of the following standards must be met: 1. Age range from 18 to 65 years old (including boundary values), both male and female; 2. Single or recurrent episodes (296.2/296.3) that meet the diagnostic criteria for depression in DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition); 3. During the screening and baseline periods, the total score of the Montgomery Asperger Depression Rating Scale (MADRS) was = 26 points; 4. Screening and baseline periods, with a Clinical Global Impression Scale Disease Severity (CGI-S) score of = 4 points; 5. Voluntary participation in clinical trials, able to sign informed consent forms, and able to understand and comply with research procedures. Exclusion Criteria: - Those who meet any of the following criteria cannot be included in this experiment: 1. Individuals with a history of severe drug allergies or allergies to Piper Piper (pepper plant) or Duloxetine; 2. Those who have used at least two antidepressants in sufficient dosage and duration (treated according to the maximum dosage in the instructions for at least 4 weeks) in a single or current episode in the past but still have no effect; 3. Those who have been ineffective in using Duloxetine in sufficient amounts during the previous treatment course; 4. The patients of depression secondary to other mental or physical illnesses; 5. Patients of depression with accompanying psychiatric symptoms; 6. Significant suicidal attempt or behavior within the past year, with a score of = 3 on the 10th item (suicidal ideation) of the MADRS scale; 7. During the baseline period, those with a reduction rate of = 25% in the MADRS scale score compared to the screening period; 8. Individuals with a history of epileptic seizures (excluding convulsions caused by febrile seizures in children); 9. Individuals who have received depression related systemic physical therapy within 3 months prior to their first administration: modified electroconvulsive therapy (MECT), transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), deep brain stimulation (DBS), phototherapy, or systemic psychotherapy; 10. Systematically receiving antidepressant treatment within the first 2 weeks of randomization, or discontinuing antidepressant medication for less than 5 half-lives before randomization; 11. Individuals with severe unstable cardiovascular disease, liver disease, kidney disease, blood disease, endocrine disease, and other physical diseases or medical history; 12. Accompanied by a history of malignant tumors (excluding cured skin basal cell carcinoma and cervical carcinoma in situ); 13. Screening or baseline electrocardiogram abnormalities that have clinical significance and are deemed unsuitable for inclusion by investigators, such as male QTcF = 450 ms, female QTcF = 470 ms, or having a history of long QT syndrome; 14. A history of symptomatic orthostatic hypotension (i.e. orthostatic syncope) with clinical significance; 15. During the screening or baseline period, TBIL is above 2 times the upper limit of normal value, and ALT or AST is above 2 times the upper limit of normal value; Cr is higher than 1.2 times the upper limit of normal value; 16. Thyroid dysfunction (TSH above 1.2 times the upper limit of normal value or below 0.8 times the lower limit of normal value) or the presence of hyperthyroidism or hypothyroidism determined by the investigators; 17. Individuals with a history of elevated intraocular pressure or narrow angle glaucoma; 18. Screening period, drug abuse screening positive individuals; 19. A history of alcohol dependence within one year prior to screening; 20. Pregnant and lactating women, male or female subjects who have a family planning or are unable to take effective contraceptive measures within 30 days after signing the informed consent form and ending the trial; 21. Screening for individuals who have participated in clinical trials and taken investigational drugs within the first 30 days; 22. The investigators believe that the subjects have poor compliance or there are other clinical, social, or family factors that are not suitable for enrollment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo group
(1 pill of 25 mg JS1-1-01 placebo pills +1 pill of 50 mg JS1-1-01 placebo pills+1 pill of duloxetine hydrochloride placebo capsule)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.
JS1-1-01 low-dose group
(1 pill of 25 mg JS1-1-01 pills +1 pill of 50 mg JS1-1-01 placebo pills +1 pill of duloxetine hydrochloride placebo capsule)/time, 2 times/day, administered postprandial, for 8 consecutive weeks.
JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules
(1 pill of 25 mg JS1-1-01 placebo pills+1 pill of 50 mg JS1-1-01 pills +1 pill of Duloxetine hydrochloride placebo capsule)/time, 2 times/day, administered postprandial, for 8 consecutive weeks.
JS1-1-01 high-dose group
(1 pill of 25 mg JS1-1-01 pills +1 pill of 50 mg JS1-1-01 pills +1 pill of Duloxetine hydrochloride placebo capsule)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.
Active drug group
(1 Duloxetine hydrochloride enteric coated capsule+1 pill of 25mg JS1-1-01 placebo pills+1 pill of 50mg JS1-1-01 placebo pills)/dose, 2 times per day, administered postprandial, for 8 consecutive weeks.

Locations

Country Name City State
China Hebei Provincial Mental Health Center Baoding Hebei
China Capital Medical University Affiliated Anding Hospital Beijing Beijing
China Chongqing 11th People's Hospital Chongqing Chongqing
China Chongqing Mental Health Center Chongqing Chongqing
China Daqing Third Hospital Daqing Heilongjiang
China The Affiliated Brain Hospital of Guangzhou Medical University Guangzhou Guangdong
China Huzhou Third People's Hospital Huzhou Zhejiang
China Shandong Provincial Mental Health Center Jinan Shandong
China The First Affiliated Hospital of Kunming Medical University Kunming Yunnan
China Jiangxi Provincial Psychiatric Hospital Nanchang Jiangxi
China Peking University Sixth Hospital Peking Beijing
China The First Hospital of Hebei Medical University Shijiazhuang Hebei
China Jilin Provincial Neuropsychiatric Hospital Siping Jilin
China Tianjin Anding Hospital Tianjin Tianjin
China Ürümqi Fourth People's Hospital Ürümqi Xinjiang
China Wuxi Mental Health Center Wuxi Jiangsu
China Zhenjiang Mental Health Center Zhenjiang Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Tasly Pharmaceutical Group Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The change in MADRS total score from baseline There are a total of 10 projects in Montgomery-Asberg Depression Rating Scale(MADRS), each with a 7-point scoring system ranging from 0 to 6 points. The higher the score, the more severe the degree of depression. 8 weeks
Secondary The change in HAMD-17 total score from baseline There are a total of 17 projects in Hamilton Depression Scale-17(HAMD-17). Scores are distributed on a scale of 0 to 53. A score above 24 indicates severe depression, a score of 17 indicates moderate depression, and a score below 7 indicates no depressive symptoms. 8 weeks
Secondary The effective rate of MADRS The effective definition of MADRS is that the reduction rate of MADRS score relative to baseline is = 50%. 8 weeks
Secondary The effective rate of HAMD-17 The effective definition of HAMD-17 is that the reduction rate of HAMD-17 score relative to baseline is = 50%. 8 weeks
Secondary The response rate of MADRS The response definition of MADRS is that the score = 12 points. 8 weeks
Secondary The response rate of HAMD-17 The response definition of HAMD-17 is that the score = 7 points. 8 weeks
Secondary The change in CGI-I and CGI-S total score from baseline Perform the Clinical Global Impression Scale (CGI-S) score from Visit 1 to Visit 7, and perform the Clinical Global Impression Scale (CGI-I) score from Visit 3 to Visit 7.The highest score is 7 points, and the higher the score, the more severe the condition will be. 8 weeks
Secondary The change in HAMA total score from baseline There are a total of 14 projects in Hamilton Anxiety Scale(HAMA), each with a 5-point scoring system ranging from 0 to 4 points. A total score of less than 6 on the scale is considered normal, a score of 7-14 indicates possible anxiety, a score of 15-20 indicates certain anxiety, a score of 21-28 indicates obvious anxiety, and a total score of more than 28 indicates severe anxiety. The higher the score, the more severe the anxiety. 8 weeks
Secondary The change in MADRS Single item score from baseline The higher the score, the more severe the degree of depression. 8 weeks
Secondary The change in HAMD-17 factor score from baseline The higher the score, the more severe the degree of depression. 8 weeks
Secondary The change in SHAPS total score from baseline There are a total of 14 projects in Snaith-Hamilton Pleasure Scale(SHAPS), each with a 4-point scoring system ranging from 1 to 4 points. Scores are distributed between 14-56 points. The higher the score, the more severe the anhedonia. 8 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A